Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix + Prevenar 13 refers to the simultaneous administration of two pediatric vaccines: Infanrix, a hexavalent combination vaccine (DTPa-HBV-IPV/Hib) that protects against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and *Haemophilus influenzae* type b; and Prevenar 13 (Pneumococcal 13-valent Conjugate Vaccine), which protects against infections caused by thirteen serotypes of *Streptococcus pneumoniae*. Both are inactivated vaccines administered intramuscularly at different injection sites during the same visit. The mechanism of action for both is immunization via induction of specific antibodies against their respective antigens. This co-administration is common in national immunization programs to provide broad protection in infancy[3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Infanrix + Prevenar 13.